Drug that delays spread of prostate cancer
18 Nov 2018
The study made by German drug maker Bayer and Finland’s Orion resulted in a drug that can slow down the spread of prostate cancer to other body parts. The companies stated that the study on men with non-metastatic prostate cancer was not showing any result or development by hormonal therapy and that set the main goal of oral drug darolutamide by delaying the speed. The U.S. Food and Drug Administration has granted the “fast track” designation to darolutamide which would speed up the marketing approval required from the health authorities.